The New England journal of medicine, 2019-06, Vol.380 (26), p.2518-2528
2019
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
- Ist Teil von
- The New England journal of medicine, 2019-06, Vol.380 (26), p.2518-2528
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Patients with interstitial lung disease associated with systemic sclerosis were treated with usual care plus placebo or nintedanib. The annual rate of change in forced vital capacity assessed over a 52-week period was −52.4 ml per year with nintedanib and −93.3 ml per year with placebo. There were no differences in other measures of systemic sclerosis.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1903076Titel-ID: cdi_proquest_journals_2247765596
- Format
- –
- Schlagworte
- Administration, Oral, Adult, Clinical trials, Computed tomography, Diarrhea, Diarrhea - chemically induced, Disease Progression, Double-Blind Method, Double-blind studies, Enzyme inhibitors, Enzyme Inhibitors - adverse effects, Enzyme Inhibitors - therapeutic use, Female, Fibrosis, Humans, Indoles - adverse effects, Indoles - therapeutic use, Lung diseases, Lung Diseases, Interstitial - drug therapy, Lung Diseases, Interstitial - etiology, Lung Diseases, Interstitial - physiopathology, Male, Middle Aged, Mycophenolic acid, Oral administration, Patients, Protein-tyrosine kinase, Protein-Tyrosine Kinases - antagonists & inhibitors, Pulmonary fibrosis, Pulmonary hypertension, Rheumatology, Scleroderma, Scleroderma, Systemic - complications, Scleroderma, Systemic - drug therapy, Sensitivity analysis, Skin, Systemic sclerosis, Technical communication, Vital Capacity